TriGemX Bio and TCGX Acquisition Corp. Announce Confidential Submission of Draft Registration Statement on Form S-4 in Connection with Proposed Business Combination
TriGemX Bio And TCGX Acquisition File Form S-4; Expect To Close Combination In Q1 2027 And Trade On Nasdaq Under Ticker Symbol 'TGEM'
TriGemX Bio and TCGX Acquisition Corp. Announce Business Combination Agreement to Create Publicly Listed Company to Develop Elismetrep, a Potential First-in-Class Treatment for Migraine
TriGemX Bio To Go Public Through Merger With TCGX Acquisition, Plans Nasdaq Listing Under TGEM; Upon Closing, Combined Company Expected to Receive ~$246M Of Gross Proceeds
TCGX Acquisition Corp. II Announces Pricing of $100,000,000 Initial Public Offering
TCGX Acquisition Corp. Announces Completion of its Initial Public Offering
TCGX Acquisition Corp. Announces Pricing of $75,000,000 Initial Public Offering
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.